Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.40 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996992 | 0.82 | F2 (0.50) | PRSS1MAPTF2PRSS2PRSS3 | |
| SCHEMBL12514072 | 0.80 | AOC3 (0.44) | ADRA2AADRA2BADRA2C | |
| SCHEMBL13716049 | 0.79 | PRSS1 (0.66) | ADRA2AADRA2BADRA2CPRSS1F2 | |
| SCHEMBL3772999 | 0.79 | GRIN2D (0.58) | PRSS1MAPTF2 | |
| SCHEMBL1445800 | 0.79 | PRSS1 (0.39) | ADRA2APRSS1F2PRSS2PRSS3 | |
| SCHEMBL526383 | 0.76 | MAPT (0.58) | ADRA2AADRA2BADRA2CMAPTLMNA | |
| SCHEMBL10310275 | 0.76 | MAPT (0.56) | MAPTLMNA | |
| SCHEMBL7525218 | 0.76 | KDM4E (0.37) | ADRA2AADRA2BADRA2CPRSS1MAPT | |
| SCHEMBL25993003 | 0.76 | PRSS1 (0.43) | PRSS1MAPTF2PRSS2PRSS3 | |
| SCHEMBL166139 | 0.76 | KIF11 (0.55) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160332-A1 | a2-Adrenoceptor Ligands | THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABE (IE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160332-A1 | a2-Adrenoceptor Ligands | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885ADRA2B 5/4885ADRA2C 3/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | ADRA2A 3680/4885ADRA2B 3825/4885ADRA2C 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.